Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli

Infection and Immunity

Volumn 73, Issue 1, 2005, Pages 258-267

  Ranallo, Ryan T ^a   Fonseka, C Piyumi ^a   Cassels, Fred ^a   Srinivasan, Jay ^a   Venkatesan, Malabi M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DNA; ESCHERICHIA COLI ENTEROTOXIN; GENTAMICIN;

ANIMAL MODEL; ANTIBODY PRODUCING CELL; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GUINEA PIG; HELA CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MUCOSAL IMMUNITY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHIGELLA FLEXNERI; SHIGELLOSIS; STRAIN DIFFERENCE;

ANIMALS; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FIMBRIAE PROTEINS; GUINEA PIGS; HELA CELLS; HUMANS; MALE; PLASMIDS; SHIGELLA FLEXNERI; SHIGELLA VACCINES; VACCINATION; VACCINES, SYNTHETIC;

EID: 11144292686     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.1.258-267.2005     Document Type: Article

References (57)

1. Altboum, Z., E. M. Barry, G. Losonsky, J. E. Galen, and M. M. Levine. 2001. Attenuated Shigella flexneri 2a ΔguaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect. Immun. 69:3150-3158.
2. Altboum, Z., M. M. Levine, J. E. Galen, and E. M. Barry. 2003. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain. Infect. Immun. 71:1352-1360.
3. Andersen, R. J., M. F. Pasetti, M. B. Sztein, M. M. Levine, and F. R. Noriega. 2000. DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine 18:2193-2202.
4. Barry, E. M., Z. Altboum, G. Losonsky, and M. M. Levine. 2003. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 21:333-340.
5. Barzu, S., J. Arondel, S. Guillot, P. J. Sansonetti, and A. Phalipon. 1998. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602. Infect. Immun. 66:77-82.
6. Barzu, S., A. Fontaine, P. Sansonetti, and A. Phalipon. 1996. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Infect. Immun. 64:1190-1196.
7. Cersini, A., M. C. Martino, I. Martini, G. Rossi, and M. L. Bernardini. 2003. Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants. Infect. Immun. 71:7002-7013.
8. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, P. K. Neogy, B. Stanton, N. Huda, M. U. Khan, B. A. Kay, M. R. Khan, et al. 1988. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158:372-377.
9. Cossart, P., and P. J. Sansonetti. 2004. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 304:242-248.
10. Coster, T. S., C. W. Hoge, L. L. VanDeVerg, A. B. Hartman, E. V. Oaks, M. M. Venkatesan. D. Cohen, G. Robin, A. Fontaine-Thompson, P. J. Sansonetti, and T. L. Hale. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67:3437-3443.
11. Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59:4310-4317.
12. Douce, G., V. Giannelli, M. Pizza, D. Lewis, P. Everest, R. Rappuoli, and G. Dougan. 1999. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67:4400-4406.
13. Douce, G., M. M. Giuliani, V. Giannelli, M. G. Pizza, R. Rappuoli, and G. Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16:1065-1073.
14. DuPont, H. L., M. M. Levine, R. B. Hornick, and S. B. Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
15. Elsinghorst, E. A. 1994. Measurement of invasion by gentamicin resistance. Methods Enzymol. 236:405-420.
16. Evans, D. G., T. K. Satterwhite, D. J. Evans, Jr., and H. L. DuPont. 1978. Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen. Infect. Immun. 19:883-888.
17. Excler, J.-L. 2003. State of the art of new vaccine research and development. World Health Organization, Geneva, Switzerland.
18. Formal, S. B., E. H. Labrec, T. H. Kent, and S. Falkow. 1965. Abortive intestinal infection with an Escherichia coli-Shigella flexneri hybrid strain. J. Bacteriol. 89:1374-1382.
19. Froehlich, B. J., A. Karakashian, L. R. Melsen, J. C. Wakefield, and J. R. Scott. 1994. CooC and CooD are required for assembly of CSl pili. Mol. Microbiol. 12:387-401.
20. Galan, J. E., K. Nakayama, and R. Curtiss III. 1990. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 94:29-35.
21. Giron, J. A., J. G. Xu, C. R. Gonzalez, D. Hone, J. B. Kaper, and M. M. Levine. 1995. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908. Vaccine 13:939-946.
22. Guerrant, R. L., L. L. Brunton, T. C. Schnaitman, L. I. Rebhun, and A. G. Gilman. 1974. Cyclic adenosine monophosphate and alteration of Chinese hamster ovary cell morphology: a rapid, sensitive in vitro assay for the enterotoxins of Vibrio cholerae and Escherichia coli. Infect. Immun. 10:320-327.
23. Haan, L., W. R. Verweij, M. Holtrop, R. Brands, G. J. van Scharrenburg, A. M. Palache, E. Agsteribbe, and J. Wilschut. 2001. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19:2898-2907.
24. Hale, T. L. 1991. Genetic basis of virulence in Shigella species. Microbiol. Rev. 55:206-224.
25. Hartman, A. B., L. L. Van de Verg, H. H. Collins, Jr., D. B. Tang, N. O. Bendiuk, D. N. Taylor, and C. J. Powell. 1994. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect. Immun. 62:412-420.
26. Hartman, A. B., and M. M. Venkatesan. 1998. Construction of a stable attenuated Shigella sonnei ΔvirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect. Immun. 66:4572-4576.
27. Hathaway, L. J., G. E. Griffin, P. J. Sansonetti, and J. D. Edgeworth. 2002. Human monocytes kill Shigella flexneri but then die by apoptosis associated with suppression of proinflammatory cytokine production. Infect. Immun. 70:3833-3842.
28. Jennison, A. V., and N. K. Verma. 2004. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol. Rev. 28:43-58.
29. Kang, H. Y., and R. Curtiss III. 2003. Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol. Med. Microbiol. 37:99-104.
30. Kaper, J. B., J. P. Nataro, and H. L. Mobley. 2004. Pathogenic Escherichia coli Nat. Rev. Microbiol. 2:123-140.
31. Karnell, A., A. Li, C. R. Zhao, K. Karlsson, B. M. Nguyen, and A. A. Lindberg. 1995. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13:88-99.
32. Katz, D. E., T. S. Coster, M. K. Wolf, F. C. Trespalacios, D. Cohen, G. Robins, A. B. Hartman, M. M. Venkatesan, D. N. Taylor, and T. L. Hale. 2004. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Immun. 72:923-930.
33. Koprowski, H., II, M. M. Levine, R. J. Andersen, G. Losonsky, M. Pizza, and E. M. Barry. 2000. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile entetotoxin of enterotoxigenic Escherichia coli. Infect. Immun. 68:4884-4892.
34. Kotloff, K. L., F. Noriega, G. A. Losonsky, M. B. Sztein, S. S. Wasserman, J. P. Nataro, and M. M. Levine. 1996. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun. 64:4542-4548.
35. Kotloff, K. L., F. R. Noriega, T. Samandari, M. B. Sztein, G. A. Losonsky, J. P. Nataro, W. D. Picking, E. M. Barry, and M. M. Levine. 2000. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun. 68:1034-1039.
36. Levine, M. M., H. L. DuPont, S. B. Formal, R. B. Hornick, A. Takeuchi, E. J. Gangarosa, M. J. Snyder, and J. P. Libonati. 1973. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J. Infect. Dis. 127:261-270.
37. Lin, T. T., S. Q. Li, Z. S. Zhang, J. P. Zheng, X. L. Liu, G. Luo, and C. F. Huang. 2003. Simultaneous expression of CS3 colonization factor antigen and LT-B/ST fusion enterotoxin antigen of enterotoxigenic Escherichia coli by attenuated Shigella flexneri 2a. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35:49-54.
38. Marcato, P., G. Mulvey, R. J. Read, K. Vander Helm, P. N. Nation, and G. D. Armstrong. 2001. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J. Infect. Dis. 183:435-443.
39. Meitert, T., E. Pencu, L. Ciudin, and M. Tonciu. 1984. Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch. Roum. Pathol. Exp. Microbiol. 43:251-278.
40. Mel, D. M., B. L. Arsic, M. L. Radovanovic, and S. A. Litvinjenko. 1974. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol. Acad. Sci. Hung. 21:109-114.
41. Mollenkopf, H., G. Dietrich, and S. H. Kaufmann. 2001. Intracellular bacteria as targets and carriers for vaccination. Biol. Chem. 382:521-532.
42. Noriega, F. R., G. Losonsky, J. Y. Wang, S. B. Formal, and M. M. Levine. 1996. Further characterization of ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect. Immun. 64:23-27.
43. Peltola, H., A. Slitonen, H. Kyronseppa, I. Simula, L. Mattila, P. Oksanen, M. J. Kataja, and M. Cadoz. 1991. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338:1285-1289.
44. Ryan, E. J., E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, R. Rappuoli, and K. H. Mills. 1999. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67:6270-6280.
45. Sakellaris, H., G. P. Munson, and J. R. Scott. 1999. A conserved residue in the tip proteins of CS1 and CFA/I pili of enterotoxigenicEscherichia coli that is essential for adherence. Proc. Natl. Acad. Sci. USA 96:12828-12832.
46. Savelkoul, P. H., G. A. Willshaw, M. M. McConnell, H. R. Smith, A. M. Hamers, B. A. van der Zeijst, and W. Gaastra. 1990. Expression of CFA/I fimbriae is positively regulated. Microb. Pathog. 8:91-99.
47. Smyth, C. J., M. B. Marron, J. M. Twohig, and S. G. Smith. 1996. Fimbrial adhesins: similarities and variations in structure and biogenesis. FEMS Immunol. Med. Microbiol. 16:127-139.
48. Szakal, D., I. Gado, and T. Pal. 2001. A colony blot immunoassay to detect enteroinvasive Escherichia coli and Shigella in water samples. J. Appl. Microbiol. 90:229-236.
49. Tamura, S., H. Asanuma, T. Tomita, K. Komase, K. Kawahara, H. Danbara, N. Hattori, K. Watanabe, Y. Suzuki, T. Nagamine, et al. 1994. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12:1083-1089.
50. Tamura, S., A. Yamanaka, M. Shimohara, T. Tomita, K. Komase, Y. Tsuda, Y. Suzuki, T. Nagamine, K. Kawahara, H. Danbara, et al. 1994. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12:419-426.
51. Tsuji, T., T. Honda, and T. Miwatani. 1984. Comparison of effects of nicked and unnicked Escherichia coli heat-labile enterotoxin on Chinese hamster ovary cells. Infect. Immun. 46:94-97.
52. Venkatesan, M. M., A. B. Hartman, J. W. Newland, V. S. Ivanova, T. L. Hale, M. McDonough, and J. Butterton. 2002. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect. Immun. 70:2950-2958.
53. Verweij, W. R., L. de Haan, M. Holtrop, E. Agsteribbe, R. Brands, G. J. van Scharrenburg, and J. Wilschut. 1998. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16:2069-2076.
54. Wang, J., L. Li, J. Zheng, J. Yu, X. Yang, Y. Geng, B. Lai, Y. Wang, and L. Si. 2003. Highly efficient expression, purification of recombinant LTB protein and its activity against mucosal immunoadjuvant by nasal immunization. Chin. Med. J. (England) 116:1115-1117.
55. Wu, S., D. W. Pascual, J. L. VanCott, J. R. McGhee, D. R. Maneval, Jr., M. M. Levine, and D. M. Hone. 1995. Immune responses to novel Escherichia coli and Salmonella typhimurium vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic E. coli in the absence of the CFA/I positive regulator cfaR. Infect. Immun. 63:4933-4938.
56. Yuki, Y., and H. Kiyono. 2003. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13:293-310.
57. Zheng, J. P., L. C. Wang, P. Wang, G. Luo, S. Q. Li, H. Q. Duan, C. F. Huang, and Z. S. Zhang. 2003. Co-expression of CFA/I and CS6 of enterotoxigenic Escherichia coli (ETEC) in Shigella flexneri 2a T32 derivative strain FWL01. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35:1005-1010.